{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-26-000018","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.034617+00:00","generated_at":"2026-05-15T01:05:13.125278+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track","bullets":["Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.","Cash $67.2M at March 31, 2026; post-merger cash runway expected through 2027.","Merger with Clywedog expected mid-2026; combined company to trade as CLYD.","Doug Swirsky appointed CFO effective May 1, 2026.","VTP-1000 celiac trial data from multiple ascending dose portion expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-26-000018","json":"https://secwatch.observer/filing/0001828185-26-000018.json","markdown":"https://secwatch.observer/filing/0001828185-26-000018.md","text":"https://secwatch.observer/filing/0001828185-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818526000018/0001828185-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818526000018/brns-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:05:13.125278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef1653a98e098ca85ca2e8c81c4d694ecf99d1e9","claim":"Barinthus Biotherapeutics plc. reported quarter ended March 31, 2026 results: net income net loss attributable to its shareholders of $5.5 million, or $(0.14) per share, EPS $(0.14) per share.","evidence_excerpt":"For the first quarter of 2026, the Company generated a net loss attributable to its shareholders of $5.5 million, or $(0.14) per share on both basic and fully diluted bases","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818526000018/0001828185-26-000018-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Net income","value":"net loss attributable to its shareholders of $5.5 million, or $(0.14) per share"},{"label":"EPS","value":"$(0.14) per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}